C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N.

Oxford Nanopore Technologies PLC (LSE:ONT) has secured a £70 million investment from French in-vitro diagnostics (IVD) company bioMérieux, in exchange for a 3.5% stake.

On August 13th, China's State Council issued a 24-point guideline covering six areas.

VC investment in medtech fell across 2022, and the downward trend in deal value continued in the first quarter of 2023. The second quarter brought potential signs that a recovery is starting. Deal value ticked up from $2.5 billion to $2.8 billion between the first and second quarters, and the number of deals rose from 183 to 189.

Mirxes Holding Company Limited, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today the successful completion of its Series D funding round, securing a total of US$50 million.

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Home health testing company SiPhox Health announced on Wednesday that it has raised $10 million in a seed financing round and $17 million in a Series A round.

Co-Diagnostics announced on Tuesday that it has been awarded two grants from the Bill and Melinda Gates Foundation totaling $2.3 million for its tuberculosis and human papillomavirus tests.

Beijing Hotgen Biotech Co., Ltd（688068.SH）released an announcement on July 6, the company intends to use its own funds together with Qingdao Chuangjing Private Equity Fund Management Co., Hangzhou Bioer Technology Co.,Ltd, Anhui Yaoan Investment Group Co. and Shaoxing Guochuang Zhende Medical (603301) Industry Phase I Equity Investment Partnership (Limited Partnership) co-finance and participate in the investment in Tristar Conrad.

On June 29, Merck announced an investment of approximately 70 million euros to expand its Nantong Life Science Center in the heart of the Yangtze River Delta region.